Autologous Bone Marrow-derived Mesenchymal Stem Cells for Interstitial Fibrosis and Tubular Atrophy: a Pilot Study

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2021 Sep 8

PMID 34493167

Citations 1

Authors

Lei Zhang

Xingqiang Lai

Yuhe Guo

Junjie Ma

Jiali Fang

Guanghui Li

Lu Xu

Wei Yin

Zheng Chen

Affiliations

Soon will be listed here.

Abstract

Background: Mesenchymal stem cells (MSCs)-based therapy has shown promising results for renal injury. In this study, the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating nonspecific interstitial fibrosis and tubular atrophy (IFTA) were evaluated.

Methods: From March 2011 to January 2013, 11 renal transplanted patients with IFTA were recruited. At baseline, patients were given one intra-arterial infusion of BM-MSCs; 7 days and 1 month later, another two intravenous infusions of cells were followed. Serum creatinine, creatinine clearance rate, and serum cystatin-C at baseline and 7 days, 1 month, 3 months, 6 months, and 12 months after the intra-arterial infusion of BM-MSCs were used to assess renal function. At baseline and 6 months, histological examination based on hematoxylin-eosin, Masson's trichrome and periodic acid-Schiff staining and immunohistochemistry for transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF) was performed. Adverse events were recorded to evaluate the safety of BM-MSCs treatment.

Results: At 12 months, the renal function of 6 patients (54.5%) was improved, 3 (27.3%) were stable and 2 (18.2%) were worsened. At 6 months, the mean IFTA scores of all participators were similar with the baseline (1.73 ± 0.41 vs.1.50 ± 0.0.77, = 0.242); however, it was significantly decreased when only 6 patients with improved renal function were analyzed (1.67 ± 0.41 vs. 1.08 ± 0.20, = 0.013). Besides, decreased expression of TGF-β1 and CTGF were also observed at 6 months. During 1 year follow-up period, only two minor complications including infection and allergy were observed.

Conclusion: Our results demonstrated that autologous BM-MSCs are safe and beneficial for IFTA patients. : MSCs: mesenchymal stem cells; BM-MSCs: marrow-derived mesenchymal stem cells; IFTA: interstitial fibrosis and tubular atrophy; CAN: chronic allograft nephropathy; CNIs: calcineurin inhibitors; Scr: serum creatinine; CCr: creatinine clearance rate; Cys-C: cystatin-C; TGF-β1: transforming growth factor β1; CTGF: connective tissue growth factor.

Citing Articles

Intra-Arterial Stem Cell Injection for Treating Various Diseases: A New Frontier in Interventional Radiology.

Rouzbahani M, Ghanaati H Cardiovasc Intervent Radiol. 2025; 48(3):288-296.

PMID: 39789253 DOI: 10.1007/s00270-024-03947-y.

Trans-Arterial Stem Cell Injection (TASI): The Role of Interventional Radiology in Regenerative Medicine.

Taninokuchi Tomassoni M, Zhou Y, Braccischi L, Modestino F, Fukuda J, Mosconi C J Clin Med. 2024; 13(3).

PMID: 38337604 PMC: 10856532. DOI: 10.3390/jcm13030910.

References

Erpicum P, Weekers L, Detry O, Bonvoisin C, Delbouille M, Gregoire C . Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney Int. 2018; 95(3):693-707. DOI: 10.1016/j.kint.2018.08.046. View

Sharma V, Bologa R, Xu G, Li B, Mouradian J, Wang J . Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int. 1996; 49(5):1297-303. DOI: 10.1038/ki.1996.185. View

Pan G, Chen Z, Xu L, Zhu J, Xiang P, Ma J . Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study. Oncotarget. 2016; 7(11):12089-101. PMC: 4914271. DOI: 10.18632/oncotarget.7725. View

Najafian B, Kasiske B . Chronic allograft nephropathy. Curr Opin Nephrol Hypertens. 2008; 17(2):149-55. DOI: 10.1097/MNH.0b013e3282f4e514. View

El-Ansary M, Saadi G, Abd El-Hamid S . Mesenchymal stem cells are a rescue approach for recovery of deteriorating kidney function. Nephrology (Carlton). 2012; 17(7):650-7. DOI: 10.1111/j.1440-1797.2012.01622.x. View

Vanhove T, Kinashi H, Nguyen T, Metalidis C, Poesen K, Naesens M . Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis. Transpl Int. 2017; 30(7):695-705. DOI: 10.1111/tri.12960. View

Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W . Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2012; 95(1):161-8. DOI: 10.1097/TP.0b013e3182754c53. View

Chen J, Li L, Wen J, Tang Z, Ji S, Sha G . Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. Transplant Proc. 2008; 40(5):1411-5. DOI: 10.1016/j.transproceed.2008.03.096. View

Li G, Jiang W, Tian J, Qu G, Zhu H, Fu F . In vitro and in vivo antifibrotic effects of rosmarinic acid on experimental liver fibrosis. Phytomedicine. 2009; 17(3-4):282-8. DOI: 10.1016/j.phymed.2009.05.002. View

10.

Franquesa M, Herrero E, Torras J, Ripoll E, Flaquer M, Goma M . Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev. 2012; 21(17):3125-35. PMC: 3495114. DOI: 10.1089/scd.2012.0096. View

11.

Yang H, Atala A, Yoo J . Kidney regeneration approaches for translation. World J Urol. 2019; 38(9):2075-2079. DOI: 10.1007/s00345-019-02999-x. View

12.

Duffy M, Griffin M . Back from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis. Stem Cell Res Ther. 2015; 5(5):109. PMC: 4338850. DOI: 10.1186/scrt497. View

13.

Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Aparecida Cavinato R . Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2010; 6(2):412-22. PMC: 3052234. DOI: 10.2215/CJN.04950610. View

14.

Pankewycz O, Leca N, Kohli R, Weber-Shrikant E, Said M, Alnimri M . Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. Transplant Proc. 2011; 43(2):519-23. DOI: 10.1016/j.transproceed.2011.01.033. View

15.

Cheng K, Rai P, Plagov A, Lan X, Kumar D, Salhan D . Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms. Exp Mol Pathol. 2013; 94(3):466-73. PMC: 3647016. DOI: 10.1016/j.yexmp.2013.03.002. View

16.

McGrath J, Shehata M . Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transplant Proc. 2001; 33(3):2193-5. DOI: 10.1016/s0041-1345(01)01939-x. View

17.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D . The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2017; 18(2):293-307. PMC: 5817248. DOI: 10.1111/ajt.14625. View

18.

Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C . Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020; 11(1):336. PMC: 7397631. DOI: 10.1186/s13287-020-01852-y. View

19.

Pan M, Zhang M, Ni H, Chen J, Xu M, Phillips A . Inhibition of TGF-β1/Smad signal pathway is involved in the effect of Cordyceps sinensis against renal fibrosis in 5/6 nephrectomy rats. Food Chem Toxicol. 2013; 58:487-94. DOI: 10.1016/j.fct.2013.04.037. View

20.

Li K, Han Q, Yan X, Liao L, Zhao R . Not a process of simple vicariousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubular epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev. 2009; 19(8):1267-75. DOI: 10.1089/scd.2009.0196. View